Emergent BioSolutions Q2 FY26 net loss widens to $180.2 million; revenue rises 66% to $234.3 million

Reuters2026/08/05 20:53

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Emergent BioSolutions posted Q2 revenue of $234.3 million, up 66% year over year; GAAP net loss widened to $180.2 million on a $191.3 million non-cash impairment.
GAAP gross margin rose 14 percentage points to 50%; non-GAAP adjusted EBITDA climbed to $96.5 million, lifting margin to 41% from 23%.
Naloxone revenue fell 22% to $52.4 million, while smallpox MCM revenue more than doubled to $101.6 million; other products revenue rose to $54.1 million.
Launched an organizational restructuring expected to deliver about $40 million in annualized savings, including a reduction of about 90 roles and a new Growth organization.
Cut full-year revenue outlook to $645 million-$675 million from $720 million-$760 million; projected GAAP net loss of $245 million-$225 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001367644-26-000080), on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Emergent BioSolutions Q2 FY26 net loss widens to $180.2 million; revenue rises 66% to $234.3 million

You may also like

Crypto prices